Product information and disease descriptionProduct descriptionProduct information
Co-prescribed/Concomitant therapies
5 evidence topics · 4 sources
Prior and current CIDP treatment permitted at entry to the phase 3 trial
Corticosteroids, immunosuppressants, and immunoglobulin during the phase 3 trial
Rescue therapy and return to standard of care in the phase 3 trial
Required vaccination against encapsulated bacteria in the phase 3 trial
Treatment at study entry: interim analysis of the first 40 participants
| Prior treatment group | Claseprubart 300 mg every 2 weeks (N=40), n (%) |
|---|---|
| Standard of care treated | “27 (67.5)” |
| Immunoglobulin | “19 (47.5)” |
| Oral corticosteroids | “8 (20.0)” |
| Standard of care refractory | “9 (22.5)” |
| Treatment naive | “4 (10.0)” |